Cynata Therapeutics Limited Stock EBITDA
| CYYNF Stock | USD 0.19 0.00 0.00% |
Cynata Therapeutics Limited fundamentals help investors to digest information that contributes to Cynata Therapeutics' financial success or failures. It also enables traders to predict the movement of Cynata Pink Sheet. The fundamental analysis module provides a way to measure Cynata Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cynata Therapeutics pink sheet.
Cynata |
Cynata Therapeutics Limited Company EBITDA Analysis
Cynata Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Cynata Therapeutics EBITDA | (13.56 M) |
Most of Cynata Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cynata Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Cynata Therapeutics Limited reported earnings before interest,tax, depreciation and amortization of (13.56 Million). This is 101.55% lower than that of the Healthcare sector and 113.54% lower than that of the Biotechnology industry. The ebitda for all United States stocks is 100.35% higher than that of the company.
Cynata EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cynata Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cynata Therapeutics could also be used in its relative valuation, which is a method of valuing Cynata Therapeutics by comparing valuation metrics of similar companies.Cynata Therapeutics is currently under evaluation in ebitda category among its peers.
Cynata Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 143.28 M | |||
| Shares Owned By Insiders | 14.77 % | |||
| Shares Owned By Institutions | 24.80 % | |||
| Price To Book | 2.66 X | |||
| Price To Sales | 5.53 X | |||
| Revenue | 7.77 M | |||
| Gross Profit | 7.77 M | |||
| EBITDA | (13.56 M) | |||
| Net Income | (5.45 M) | |||
| Cash And Equivalents | 26.79 M | |||
| Cash Per Share | 0.19 X | |||
| Current Ratio | 16.25 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (3.3 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 10 | |||
| Beta | 0.61 | |||
| Market Capitalization | 35.82 M | |||
| Total Asset | 26.55 M | |||
| Net Asset | 26.55 M |
About Cynata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cynata Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cynata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cynata Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.